Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth's narrower loss, rising Canadian sales and improving margins signal progress in its turnaround, even as competition and global headwinds persist.
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.95 per share a year ago.
In the most recent trading session, Canopy Growth Corporation (CGC) closed at $1.22, indicating a -2.4% shift from the previous trading day.
Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.31, marking a -2.96% move from the previous day.
Canopy Growth Corporation (CGC) closed the most recent trading day at $1.35, moving 7.53% from the previous trading session.
The latest trading day saw Canopy Growth Corporation (CGC) settling at $1.37, representing a -16.97% change from its previous close.
Canopy Growth Corporation (CGC) closed the most recent trading day at $1.36, moving 1.45% from the previous trading session.
Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors are closely watching Canadian cannabis stocks this week amid rising U.S. industry momentum. The U.S. cannabis market hit an estimated $38.5 billion in 2024 and may grow at a compound annual growth rate (CAGR) of about 11–12 percent through the late 2020s. Meanwhile, several states are advancing reform. Notably, Delaware began adult-use cannabis sales on August 1, 2025. Moreover, at the federal level, the Trump administration signaled plans to reschedule marijuana from Schedule I to Schedule III, possibly within weeks. This could ease restrictions and boost stock sentiment. Altogether, these developments underline strong thematic tailwinds. Thus, Canadian cannabis stocks with U.S. exposure stand to benefit from both legislative momentum and expanding consumer demand.